The p53 tumor suppressor pathway is dysfunctional in most colorectal cancers [3], and thus employing rational attempts reversing p53 downregulation in cancer cells by impairing p53 degradation would be a tempting strategy for colon cancer therapy. This evidence concerns the gene TP53 and colorectal cancer.